Escalon(R) Reports Second Quarter Fiscal 20... (fiscal year. For the six-month period...)

Escalon(R) Reports Second Quarter Fiscal 2008 Results

Date:2/14/2008

fiscal year.

For the six-month period ended December 31, 2007, the Company reported net revenue of $14,388,351 compared with $14,804,900 in the prior period. This decline was primarily due to decreased royalties received from the IntraLase License Agreement as a result of the settlement agreement between the Company and IntraLase dated February 27, 2007. Product revenue increased approximately 5% during the six-month period ended December 31, 2007 as compared with the same period last fiscal year. The increase was primarily related to increases in the Drew and EMI business units.

The Company reported a net loss for the six months ended December 31, 2007 of $(1,468,137), or $(0.23) per diluted share, compared with a net loss of $(1,184,220), or $(0.19) per diluted share, in the prior year period. Cost of goods sold totaled approximately $7,874,000, or 55% of product revenue, for the six-month period ended December 31, 2007, compared with $7,509,000, or 55% of product revenue, for the same period last fiscal year.

Operating expenses decreased approximately 5% during the six-month period ended December 31, 2007 as compared with the same period in the prior fiscal year. This was due to a significant decrease in legal fees related to the IntraLase litigation and to the Company's realizing the effect of the cost reduction plan implemented in the prior fiscal year.

Recap of Fiscal Second Quarter 2008

Richard J. DePiano, Chairman and Chief Executive Officer, commented, "During the second quarter, we continued to see the benefits of the restructuring plans implemented in fiscal 2007, as evidenced by our lower operating expenses for the six-month period. Further, we extended our product portfolio during the second quarter. In January, we received our third FDA market clearance since December for our VascuView(TM) Visual Ultrasound System. This follows earlier clearances to market of our MASTER-VU(R) and D3 Hematology Systems. We are very pl
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Escalon(R) Announces Promotion of Industry Veteran Barry Durante to President of Sonomed, Inc.
2. Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System
3. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results

Post Your Comments:

Escalon(R) Reports Second Quarter Fiscal 20...(fiscal year. For the six-month period...)